Boehringer Ingelheim

EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
EASD: Boehringer Ingelheim, Lilly's Jardiance holds CV benefit regardless of blood sugar starting point
Fierce Pharma
EASD
Boehringer Ingelheim
Eli Lilly
Jardiance
diabetes
Flag link:
Boehringer Ingelheim/Pharmaxis start Phase IIa trial in NASH
Boehringer Ingelheim/Pharmaxis start Phase IIa trial in NASH
GoInPharma
Boehringer Ingelheim
Pharmaxis
NASH
clinical trials
BI 1467335
Flag link:
CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana
CVS formulary knocks Lilly, BI's Jardiance in favor of J&J's Invokana
Fierce Pharma
formulary
Eli Lilly
Boehringer Ingelheim
JNJ
Invokana
diabetes
CVS Caremark
Flag link:
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
Fierce Pharma
JNJ
Invokana
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
Flag link:
This Secretive Clan Wants to Beat the World’s Biggest Drugmakers
This Secretive Clan Wants to Beat the World’s Biggest Drugmakers
Bloomberg
Boehringer Ingelheim
Flag link:
Key Humira patent gets struck down for the second time in as many months
Key Humira patent gets struck down for the second time in as many months
Fierce Pharma
Humira
patents
AbbVie
Boehringer Ingelheim
Coherus Biosciences
Flag link:
BI, Lilly hit the streets to talk up Jardiance's cardiovascular benefits
BI, Lilly hit the streets to talk up Jardiance's cardiovascular benefits
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Jardiance
drug ads
DTC advertising
Flag link:
AstraZeneca, Boehringer cry 'no class effect' after Johnson & Johnson's Invokana doubles amputations in study
AstraZeneca, Boehringer cry 'no class effect' after Johnson & Johnson's Invokana doubles amputations in study
Fierce Pharma
AstraZeneca
Boehringer Ingelheim
JNJ
Invokana
diabetes
Jardiance
amputation
Flag link:
J&J's Invokana lowers CV risk, but by enough to compete?
J&J's Invokana lowers CV risk, but by enough to compete?
BioPharma Dive
JNJ
Invokana
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Flag link:
ADA: Merck, Pfizer notch success, but late with SGLT-2 data
ADA: Merck, Pfizer notch success, but late with SGLT-2 data
BioPharma Dive
diabetes
Merck
Pfizer
SGLT2 inhibitor
Januvia
Invokana
Farxiga
Jardiance
Eli Lilly
Boehringer Ingelheim
AstraZeneca
JNJ
Flag link:
J&J Drug Prevents Heart Attacks At Cost Of Amputated Toes
J&J Drug Prevents Heart Attacks At Cost Of Amputated Toes
Forbes
JNJ
heart attacks
Invokana
diabetes
amputation. Eli Lilly
Boehringer Ingelheim
Jardiance
Flag link:
ADA preview: 5 things to watch in diabetes
ADA preview: 5 things to watch in diabetes
BioPharma Dive
ADA
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Lantus
Tresiba
JNJ
Novo Nordisk
PCSK9 inhibitors
Amgen Regeneron
Sanofi
Apple
Google
insulin
Flag link:
Boehringer Ingelheim opens large manufacturing facility in China
Boehringer Ingelheim opens large manufacturing facility in China
BioPharma Dive
Boehringer Ingelheim
China
drug manufacturing
Flag link:
Pradaxa’s 'Red Fish' go to the aquarium in new Boehringer campaign
Pradaxa’s 'Red Fish' go to the aquarium in new Boehringer campaign
Fierce Pharma
Boehringer Ingelheim
Pradaxa
drug ads
television ads
bloodthinners
Flag link:
Boehringer eyes marked sales gain, boosted by animal health
Boehringer eyes marked sales gain, boosted by animal health
Yahoo/Reuters
Boehringer Ingelheim
animal health
earnings
Flag link:
Diabetes meds from AZ, J&J and Lilly sharply cut death rates in real-world analysis
Diabetes meds from AZ, J&J and Lilly sharply cut death rates in real-world analysis
Fierce Pharma
AstraZeneca
JNJ
Eli Lilly
Boehringer Ingelheim
diabetes
Farixga
Invokana
Jardiance
SGLT2 inhibitor
Flag link:
Merck and Pfizer prep for battle with SGLT2, combo diabetes filings
Merck and Pfizer prep for battle with SGLT2, combo diabetes filings
Fierce Pharma
Merck
Pfizer
SGLT2 inhibitor
diabetes
ertugliflozin
Jardiance
Boehringer Ingelheim
Eli Lilly
JNJ
Invokana
AstraZeneca
Farxiga
Flag link:
Boehringer Ingelheim's Humira Biosimilar Under Review by EMA, FDA
Boehringer Ingelheim's Humira Biosimilar Under Review by EMA, FDA
Yahoo/GuruFocus
Boehringer Ingelheim
Humira
biosimilars
FDA
EMA
BI 695501
AbbVie
Flag link:
Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017
Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017
Yahoo
Sanofi
Boehringer Ingelheim
consumer health
animal health
Merial
Flag link:
ADA guidelines highlight new Jardiance label
ADA guidelines highlight new Jardiance label
BioPharma Dive
ADA
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Novo Nordisk
Victoza
Flag link: